111,Inc

About 111,Inc

111, Inc. operates a digital healthcare platform in China, established in 2010 by co-founders Dr. Gang Yu and Mr. Junling Liu. The duo brought extensive experience from leadership roles at global technology and e-commerce giants, including Dell, Amazon, and Yihaodian, an e-commerce venture they previously co-founded. This background in supply chain management and technology has been fundamental to the company's strategy.

The company's core mission is to digitize China's healthcare industry, connecting patients with a comprehensive network of medical services and pharmaceutical products. Its business model, described as "Technology-to-Business-to-Consumer" (T2B2C), integrates online and offline channels to create a unified healthcare ecosystem. This model empowers participants across the value chain, including pharmaceutical companies, doctors, hospitals, and pharmacies, by streamlining operations and improving efficiency. Revenue is primarily generated through the online and offline retail and wholesale of pharmaceutical and healthcare products.

111, Inc. operates several distinct business lines. Its business-to-consumer (B2C) platform, "1 Drugstore" (1药网), was one of China's first legally authorized online retail pharmacies. The business-to-business (B2B) platform, "1 Drug Mall" (1药城), functions as a one-stop procurement hub for pharmacies. Complementing these is "1 Clinic" (1诊), an internet hospital providing online consultations and electronic prescriptions. Through this integrated structure, the company aims to improve drug commercialization for manufacturers, expand patient access for doctors, and enhance healthcare management for consumers. A significant milestone was achieved on September 12, 2018, when 111, Inc. was listed on the Nasdaq stock exchange under the ticker YI, becoming the first Chinese internet health company to be publicly traded in the United States.